Business
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline.Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a
About this update from Ascentage Pharma Group International
[{"type":"image","alt":"ASCENTAGE PHARMA GROUP INTERNATIONAL","displaySize":"","headline":null,"caption":"ASCENTAGE PHARMA GROUP INTERNATIONAL","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/83c243f98269a5be00d529ddda07bc2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GOf2VIvpehDsvnIO9ha4CQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/83c243f98269a5be00d529ddda07bc2b","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline.","length":245,"tagName":"p"}]},{"val":[{"type":"text","content":"Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies.","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":375,"olType":false},{"type":"text","content":"ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration (FDA) and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies. This clearance officially opens the chapter on Ascentage Pharma’s clinical development in the field of targeted degradation and marks another major expansion to the company’s global innovative pipeline.","length":797,"tagName":"p"},{"type":"text","content":"This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.","length":232,"tagName":"p"},{"type":"text","content":"BTK is a key kinase in the B-cell receptor (BCR) signaling pathway an...